Literature DB >> 31359350

Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases.

Kristen M Beck1, Gerami D Seitzman2, Eric J Yang3, Isabelle M Sanchez3, Wilson Liao3.   

Abstract

Ocular diseases associated with atopic dermatitis (AD) may be sight-threatening. A general understanding of the pathophysiology, diagnosis, and treatment of atopic eye disease may assist dermatologists in knowing when to refer to ophthalmology and in co-managing these diseases with ophthalmologists. Ocular diseases associated with AD include eyelid dermatitis, keratoconjunctivitis, keratoconus, cataract, and retinal detachment. AD patients are also at higher risk for bacterial and viral ocular infections. The objective of this article is to provide a current review of ocular diseases that commonly affect AD patients. The pathogenesis, clinical manifestations, diagnosis, and treatment of ocular co-morbidities of AD will be discussed.

Entities:  

Mesh:

Year:  2019        PMID: 31359350     DOI: 10.1007/s40257-019-00455-5

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  3 in total

1.  Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.

Authors:  Roselie E Achten; Chantal Van Luijk; Lisa Van der Rijst; Daphne Bakker; Lotte Spekhorst; Nicolaas Zuithoff; Marie Schuttelaar; Geertruida Romeijn; Angelique Voorberg; Marijke Kamsteeg; Inge Haeck; Marlies De Graaf; Judith Thijs; Joke De Boer; Marjolein De Bruin-Weller
Journal:  Acta Derm Venereol       Date:  2022-03-11       Impact factor: 3.875

2.  Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.

Authors:  Mélanie Hébert; Susan Ruyu Qi; Eunice You; Mathieu Mercier; Patricia-Ann Laughrea
Journal:  BMJ Open Ophthalmol       Date:  2022-05

3.  Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up.

Authors:  Austin Bohner; Christina Topham; Jennifer Strunck; Dylan Haynes; Molly Brazil; John Clements; Eric Simpson; Winston Chamberlain
Journal:  Cornea       Date:  2021-05-01       Impact factor: 3.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.